Our research suggests that NeuroD1 may represent a potential therapeutic target for pancreatic cancer, inducing the reversal of the malignant phenotype of pancreatic tumor cells via transdifferentiation into neurons through gene editing or the use of differentiation-inducing agents. This evidence concerns the gene NEUROD1 and pancreatic neoplasm.